Literature DB >> 21184738

Specific inhibition of nitric oxide synthases at different time points in a murine model of pulmonary sepsis.

Matthias Lange1, Atsumori Hamahata, Daniel L Traber, Yoshimitsu Nakano, Lillian D Traber, Perenlei Enkhbaatar.   

Abstract

Excessive production of nitric oxide (NO) by NO synthase (NOS) and a subsequent oxidative stress reaction are thought to be critically involved in the pathophysiology of sepsis. Previous studies suggested that NO production by neuronal NOS (nNOS) and inducible NOS (iNOS) is implemented in the disease process at different time points after the injury. Here we tested the roles of selective pharmacological inhibition of nNOS and iNOS at different time points in a murine model of pulmonary sepsis. The injury was induced by intranasal administration of live Pseudomonas aeruginosa (3.2×10(7) colony-forming units) in C57BL/6 wild-type mice. The animals received no treatment (control) or treatment with a specific nNOS inhibitor (4 or 8h), iNOS inhibitor (4 or 8h), or non-specific NOS inhibitor (4 or 8h). In controls, the injury was associated with excessive releases of pro-inflammatory cytokines in the plasma, enhanced tissue lipid peroxidation, and decreased survival. Non-specific NOS inhibition at either time point did not influence survival and was not further investigated. While nNOS inhibition at 4h was associated with a trend toward improved survival and significantly reduced contents of lung nitrite/nitrate (NO(x)) and liver malondialdehyde, the blockade of nNOS at 8h had no effect on these parameters. In contrast, early iNOS inhibition was associated with a trend toward decreased survival and no effects on lung NO(x) and liver malondialdehyde contents, whereas later iNOS blockade was associated with decreased malondialdehyde content in liver homogenates. In conclusion, pulmonary sepsis in mice may be beneficially influenced by specific pharmacological nNOS inhibition at an earlier time point and iNOS inhibition at a later time points post-injury. Future investigations should identify the time changes of the expression and activation of NOS isoforms.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21184738     DOI: 10.1016/j.bbrc.2010.12.078

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Time profile of oxidative stress and neutrophil activation in ovine acute lung injury and sepsis.

Authors:  Matthias Lange; Csaba Szabo; Daniel L Traber; Eszter Horvath; Atsumori Hamahata; Yoshimitsu Nakano; Lillian D Traber; Robert A Cox; Frank C Schmalstieg; David N Herndon; Perenlei Enkhbaatar
Journal:  Shock       Date:  2012-05       Impact factor: 3.454

2.  Neutrophilic inflammatory response and oxidative stress in premenopausal women chronically exposed to indoor air pollution from biomass burning.

Authors:  Anirban Banerjee; Nandan Kumar Mondal; Debangshu Das; Manas Ranjan Ray
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

3.  Visualization of murine intranasal dosing efficiency using luminescent Francisella tularensis: effect of instillation volume and form of anesthesia.

Authors:  Mark A Miller; Jennifer M Stabenow; Jyothi Parvathareddy; Andrew J Wodowski; Thomas P Fabrizio; Xiaowen R Bina; Lillian Zalduondo; James E Bina
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

4.  Endothelial nitric oxide synthase deficient mice are protected from lipopolysaccharide induced acute lung injury.

Authors:  Christine M Gross; Ruslan Rafikov; Sanjiv Kumar; Saurabh Aggarwal; P Benson Ham; Mary Louise Meadows; Mary Cherian-Shaw; Archana Kangath; Supriya Sridhar; Rudolf Lucas; Stephen M Black
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 5.  Arginine and citrulline and the immune response in sepsis.

Authors:  Karolina A P Wijnands; Tessy M R Castermans; Merel P J Hommen; Dennis M Meesters; Martijn Poeze
Journal:  Nutrients       Date:  2015-02-18       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.